Clinical trial
Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced…
NCT00350961 · Rigshospitalet, Denmark, Other · Completed
Key facts
| NCT number | NCT00350961 |
|---|---|
| Title | Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma |
| Official title | Phase I-II Study of bi-Weekly Fixed Dose Rate Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma |
| Lead sponsor | Rigshospitalet, Denmark, Other |
| Collaborators | Henrik Jensen, Dept. of Oncology, Vejle Sygehus, Vejle, Denmark |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Cholangiocarcinoma |
| Intervention type | Drug |
| Interventions | Gemcitabine, Oxaliplatin, Capecitabine |
| Enrollment | 39 |
| Start date | Jun 1, 2004 |
| Completion | Feb 1, 2008 |
| First posted | Jul 11, 2006 |
| Last update posted | Aug 26, 2008 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: